This program may contribute to the resistance against traditional anti-TGF-β therapies in fibrotic kidney disease and highlights the PKM2–TEAD2 circuit as a therapeutic target distinct from EMT signaling. The gene discussed is TEAD2; the disease is kidney disorder.